B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy

Oncotarget

Volumn 6, Issue 31, 2015, Pages 30939-30956

  Shao, Fang Yuan ^a   Du, Zhi Yun ^c   Ma, Dong Lei ^b   Chen, Wen Bo ^b   Fu, Wu Yu ^a   Ruan, Bi Bo ^a   Rui, Wen ^a   Zhang, Jia Xuan ^b   Wang, Sheng ^b   Wong, Nai Sum ^d   Xiao, Hao ^e   Li, Man Mei ^b   Liu, Xiao ^a   Liu, Qiu Ying ^b   Zhou, Xiao dong ^f   Yan, Hai Zhao ^b   Wang, Yi Fei ^b   Chen, Chang Yan ^g   Liu, Zhong ^b   Chen, Hong Yuan ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^f NANCHANG UNIVERSITY   (China)

^g NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cervical cancer; Curcumin analog; Thioredoxin reductase

Indexed keywords

ACETYLCYSTEINE; ACRIDINE ORANGE; APOPTOSIS SIGNAL REGULATING KINASE 1; B5; CASPASE; CURCUMIN; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; MESSENGER RNA;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CASKI CELL LINE; CELL CYCLE ARREST; CELL VACUOLE; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIHA CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; UTERINE CERVIX CANCER; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CURCUMIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84945569605     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5132     Document Type: Article

References (68)

1. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003; 23:2425-2433.
2. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by betaphenylethyl isothiocyanate. Cancer cell. 2006; 10:241-252.
3. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free radical biology & medicine. 2000; 29:312-322.
4. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Seminars in cancer biology. 2006; 16:452-465.
5. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol. 2000; 31:475-481.
6. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends in molecular medicine. 2005; 11:571-578.
7. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free radical biology & medicine. 2005; 38:1543-1552.
8. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. The Journal of biological chemistry. 1997; 272:30615-30618.
9. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK)1. EMBO J. 1998; 17:2596-2606.
10. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997; 275:90-94.
11. Karlenius TC, Tonissen KF. Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation. Cancers. 2010; 2:209-232.
12. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002; 62:5089-5095.
13. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol. 2005; 39:813-822.
14. Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, Gulino A, Mackay AR. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. European journal of biochemistry/FEBS. 2001; 268:405-413.
15. Ceccarelli J, Delfino L, Zappia E, Castellani P, Borghi M, Ferrini S, Tosetti F, Rubartelli A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer. 2008; 123:1770-1778.
16. Miyazaki K, Noda N, Okada S, Hagiwara Y, Miyata M, Sakurabayashi I, Yamaguchi N, Sugimura T, Terada M, Wakasugi H. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy. 1998; 11:277-288.
17. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res. 2005; 11:8425-8430.
18. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:422-431.
19. Marks PA. Thioredoxin in cancer-role of histone deacetylase inhibitors. Seminars in cancer biology. 2006; 16:436-443.
20. Yoshioka J, Schreiter ER, Lee RT. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxidants & redox signaling. 2006; 8:2143-2151.
21. Holmgren A, Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods in enzymology. 1995; 252:199-208.
22. Liu Z, Du ZY, Huang ZS, Lee KS, Gu LQ. Inhibition of thioredoxin reductase by curcumin analogs. Biosci Biotechnol Biochem. 2008; 72:2214-2218.
23. Ho AT, Li QH, Okada H, Mak TW, Zacksenhaus E. XIAP activity dictates Apaf-1 dependency for caspase 9 activation. Molecular and cellular biology. 2007; 27:5673-5685.
24. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS. XIAP inhibits caspase-3 and-7 using two binding sites: evolutionarily conserved mechanism of IAPs. The EMBO journal. 2005; 24:645-655.
25. Singh T, Sharma SD, Katiyar SK. Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human non-small cell lung cancer cells in vitro and in vivo. PloS one. 2011; 6:e27444.
26. Charlot JF, Pretet JL, Haughey C, Mougin C. Mitochondrial translocation of p53 and mitochondrial membrane potential (Delta Psi m) dissipation are early events in staurosporineinduced apoptosis of wild type and mutated p53 epithelial cells. Apoptosis: an international journal on programmed cell death. 2004; 9:333-343.
27. Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB. Mitochondrial membrane potential monitored by JC-1 dye. Methods in enzymology. 1995; 260:406-417.
28. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002; 111:331-342.
29. Schwarz M, Andrade-Navarro MA, Gross A. Mitochondrial carriers and pores: key regulators of the mitochondrial apoptotic program? Apoptosis: an international journal on programmed cell death. 2007; 12:869-876.
30. Vaahtera L, Brosche M, Wrzaczek M, Kangasjarvi J. Specificity in ROS Signaling and Transcript Signatures. Antioxidants & redox signaling. 2014.
31. Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS, Lele RD. Free radicals and antioxidants in human health: current status and future prospects. The Journal of the Association of Physicians of India. 2004; 52:794-804.
32. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002; 84:131-141.
33. Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cellular signalling. 2014; 26:549-555.
34. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, Yahalom J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001; 61:439-444.
35. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8:445-544.
36. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy. 2007; 3:635-637.
37. Hardie DG. AMPK and autophagy get connected. The EMBO journal. 2011; 30:634-635.
38. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Molecular cell. 2010; 38:768-774.
39. Navarro-Yepes J, Burns M, Anandhan A, Khalimonchuk O, del Razo LM, Quintanilla-Vega B, Pappa A, Panayiotidis MI, Franco R. Oxidative stress, redox signaling, and autophagy: cell death versus survival. Antioxidants & redox signaling. 2014; 21:66-85.
40. Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A. 1982; 79:1889-1892.
41. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. The Journal of biological chemistry. 2010; 285:10850-10861.
42. Mukherjee A, Martin SG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol. 2008; 81:S57-68.
43. Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res. 2009; 53:87-103.
44. Lu J, Holmgren A. Thioredoxin system in cell death progression. Antioxidants & redox signaling. 2012; 17:1738-1747.
45. Arner ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta. 2009; 1790:495-526.
46. Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Die Pharmazie. 2011; 66:440-444.
47. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995; 55:4293-4296.
48. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 2006; 66:4410-4418.
49. Xia L, Nordman T, Olsson JM, Damdimopoulos A, Bjorkhem-Bergman L, Nalvarte I, Eriksson LC, Arner ES, Spyrou G, Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. The Journal of biological chemistry. 2003; 278:2141-2146.
50. Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. The Journal of biological chemistry. 2008; 283:11913-11923.
51. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007; 104:12288-12293.
52. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. The Journal of biological chemistry. 2005; 280:25284-25290.
53. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88:1052-1061.
54. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281:1309-1312.
55. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annual review of pharmacology and toxicology. 2007; 47:143-183.
56. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. The Journal of biological chemistry. 1999; 274:11549-11556.
57. Srinivasula SM, Ahmad M, FernandesAlnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Molecular cell. 1998; 1:949-957.
58. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO journal. 1998; 17:2215-2223.
59. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24:R453-462.
60. Runchel C, Matsuzawa A, Ichijo H. Mitogen-activated protein kinases in mammalian oxidative stress responses. Antioxidants & redox signaling. 2011; 15:205-218.
61. Owuor ED, Kong AN. Antioxidants and oxidants regulated signal transduction pathways. Biochemical pharmacology. 2002; 64:765-770.
62. Pocrnich CE, Liu H, Feng M, Peng T, Feng Q, Hutnik CM. p38 mitogen-activated protein kinase protects human retinal pigment epithelial cells exposed to oxidative stress. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2009; 44:431-436.
63. Liu B, Cheng Y, Zhang B, Bian HJ, Bao JK. Polygonatum cyrtonema lectin induces apoptosis and autophagy in human melanoma A375 cells through a mitochondria-mediated ROS-p38-p53 pathway. Cancer letters. 2009; 275:54-60.
64. Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer letters. 2011; 302:29-36.
65. Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Molecular and cellular biology. 2012; 32:2-11.
66. Du ZY, Bao YD, Liu Z, Qiao W, Ma L, Huang ZS, Gu LQ, Chan AS. Curcumin analogs as potent aldose reductase inhibitors. Archiv der Pharmazie. 2006; 339:123-128.
67. Cunniff B, Snider GW, Fredette N, Hondal RJ, Heintz NH. A direct and continuous assay for the determination of thioredoxin reductase activity in cell lysates. Analytical biochemistry. 2013.
68. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. The Journal of biological chemistry. 2003; 278:33408-33415.